117 related articles for article (PubMed ID: 31490767)
1. STAT5 and STAT5 Inhibitors in Hematological Malignancies.
Tolomeo M; Meli M; Grimaudo S
Anticancer Agents Med Chem; 2019; 19(17):2036-2046. PubMed ID: 31490767
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.
Recio C; Guerra B; Guerra-Rodríguez M; Aranda-Tavío H; Martín-Rodríguez P; de Mirecki-Garrido M; Brito-Casillas Y; García-Castellano JM; Estévez-Braun A; Fernández-Pérez L
Oncogene; 2019 Jun; 38(24):4657-4668. PubMed ID: 30783189
[TBL] [Abstract][Full Text] [Related]
3. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Polomski M; Brachet-Botineau M; Juen L; Viaud-Massuard MC; Gouilleux F; Prié G
ChemMedChem; 2021 Mar; 16(6):1034-1046. PubMed ID: 33275308
[TBL] [Abstract][Full Text] [Related]
5. Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Rondanin R; Simoni D; Maccesi M; Romagnoli R; Grimaudo S; Pipitone RM; Meli M; Cascio A; Tolomeo M
ChemMedChem; 2017 Aug; 12(15):1183-1190. PubMed ID: 28657677
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
[TBL] [Abstract][Full Text] [Related]
7. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
9. The identification and characterization of a STAT5 gene signature in hematologic malignancies.
Sonkin D; Palmer M; Rong X; Horrigan K; Regnier CH; Fanton C; Holash J; Pinzon-Ortiz M; Squires M; Sirulnik A; Radimerski T; Schlegel R; Morrissey M; Cao ZA
Cancer Biomark; 2015; 15(1):79-87. PubMed ID: 25524945
[TBL] [Abstract][Full Text] [Related]
10. STAT5 signaling in normal and pathologic hematopoiesis.
Bunting KD
Front Biosci; 2007 May; 12():2807-20. PubMed ID: 17485261
[TBL] [Abstract][Full Text] [Related]
11. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
13. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
14. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
15. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Hjort EE; Huang W; Hu L; Eklund EA
Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
[TBL] [Abstract][Full Text] [Related]
16. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
17. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Trécul A; Morceau F; Gaigneaux A; Orsini M; Chateauvieux S; Grandjenette C; Dicato M; Diederich M
Cancer Lett; 2013 Oct; 340(1):30-42. PubMed ID: 23811288
[TBL] [Abstract][Full Text] [Related]
18. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
19. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
20. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
